Aspiriant LLC Has $738,000 Position in Pfizer Inc. (NYSE:PFE)

Aspiriant LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,127 shares of the biopharmaceutical company’s stock after selling 2,412 shares during the period. Aspiriant LLC’s holdings in Pfizer were worth $738,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tallon Kerry Patrick acquired a new position in shares of Pfizer during the 4th quarter worth about $509,000. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Principal Securities Inc. increased its holdings in shares of Pfizer by 1.9% in the fourth quarter. Principal Securities Inc. now owns 84,689 shares of the biopharmaceutical company’s stock valued at $2,247,000 after purchasing an additional 1,609 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in shares of Pfizer by 12.9% in the fourth quarter. Allworth Financial LP now owns 132,932 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 15,177 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Down 1.6%

Shares of NYSE:PFE opened at $24.00 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $136.47 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.89 and a beta of 0.57. The business’s 50 day moving average is $23.14 and its 200 day moving average is $24.93. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 earnings per share. The business’s revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.17%. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.